VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies
Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as VNP40101M and cytarabine, use different ways
to stop cancer cells from dividing so they stop growing or die. Combining more than one drug
may kill more cancer cells.
PURPOSE: Phase I trial to study the effectiveness of combining VNP40101M with cytarabine in
treating patients who have hematologic malignancies, including myelodysplastic syndrome or
relapsed, refractory, or untreated leukemia.